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Cost-effectiveness of preventive treatment
of intracranial aneurysms
New data and uncertainties





Background: Previous modeling studies on treatment of unruptured intracranial aneurysms
largely disregarded detailed data on treatment risks and omitted several factors that could influ-
ence cost-effectiveness. We performed a cost-effectiveness analysis of surgical and endovascu-
lar treatment of unruptured aneurysms for different rupture rates and life expectancies, and
assessed the influence of excess mortality risks in these persons, de novo development of aneu-
rysms, and utility of awareness of having an untreated aneurysm, and also identified important
factors for which data are lacking.
Methods:We used a Markov model to compare surgical, endovascular, and no treatment of unrup-
tured intracranial aneurysms. Inputs for the model were taken mainly from meta-analyses. Direct
medical costs were derived from Dutch cost studies and expressed in 2005 Euros. We performed
sensitivity analyses to evaluate model robustness.
Results: For 50-year-old patients, treatment of unruptured aneurysms is cost-effective for all
rupture rate scenarios between 0.3% and 3.5%/year. In 70-year-old patients, treatment is not
cost-effective in men with rupture rates 1%/year and women with rupture rates 0.5%/year.
With lower utility of awareness of an untreated aneurysm, the cost-effectiveness of treatment
strongly increased. The effect of excess mortality risks on the incremental cost-effectiveness
ratios was modest. The risk of formation of new aneurysms had no relevant impact.
Conclusions: Patients’ life expectancy, risk of rupture, and utility of awareness of an untreated
aneurysm mainly define cost-effectiveness. However, important uncertainties remain on the rup-
ture risk according to size and location of the aneurysm and on the utility of awareness of
untreated aneurysm. More data on these factors are needed to define and individualize cost-
effectiveness analyses. Neurology® 2009;73:258–265
GLOSSARY
ICER  incremental cost-effectiveness ratios; ISUIA  International Study of Unruptured Intracranial Aneurysms; QALY 
quality-adjusted life-year; SAH subarachnoid hemorrhage.
Despite modern microsurgical techniques and rapidly developing endovascular treatment op-
tions, nearly half of the patients with a subarachnoid hemorrhage (SAH) from a ruptured
aneurysm die within the first weeks after the hemorrhage. Over 10% of all patients with SAH
die before reaching the hospital and cannot be salvaged.1 Patients who reach the hospital alive
may already be in a poor clinical condition from the initial bleeding and are at risk of compli-
cations such as rebleeding, secondary ischemia, and systemic complications.2,3 Prevention of
aneurysmal rupture therefore seems an attractive option, but surgical or endovascular occlusion
of intracranial aneurysms themselves carry a risk of serious complications.
In 2003, the International Study of Unruptured Intracranial Aneurysms (ISUIA) investigators
reported prospective data on the management of unruptured intracranial aneurysms.4 However,
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if so which method of aneurysm occlusion (sur-
gical clipping or endovascular coiling) should be
offered.5,6 There are no data from randomized
clinical trials yet. One trial (TEAM) has started
recently, but even if such a trial will provide an
answer eventually, for the next decade we have
to rely on other sources on which to base our
decisions. Because treatment choice requires a
comparison of acute treatment-related risks and
future rupture risk, decision analysis may be an
appropriate way to gain the best possible insight
into the balance of risks and benefits. Several
such decision and cost-effectiveness analyses
have been performed.7-11 However, in these
analyses, comparisons among surgical clipping,
endovascular coiling, and no treatment were
based on earlier estimates of complications risks
or data derived from the ISUIA only.4 Further-
more, the risk of formation and rupture of re-
current and de novo aneurysms were not
included in these models.
The objective of this study was to evaluate
and update estimates of cost-effectiveness of sur-
gical and endovascular treatment of unruptured
aneurysms for different rupture rates and differ-
ent life expectancies. Moreover, we assessed the
influence of excess mortality risks in these per-
sons, de novo aneurysm formation and utility of
awareness of having an untreated aneurysm, and
also identified factors that are pivotal in the anal-
yses for which data are lacking.
METHODS Model structure. We developed a Markov
model to estimate the expected lifetime costs and quality-adjusted
life-years (QALYs) after surgical clipping, endovascular coiling, and
no treatment of unruptured intracranial aneurysms. The model was
designed to simulate cohorts of patients with unruptured aneurysms
with various levels of rupture risk. Themodel comprises eight health
states: well with a treated or untreated aneurysm, well with a recur-
rent or de novo aneurysm, well treated after SAH, disabled (after
SAH or after treatment), and dead (figure e-1 on the Neurology®
Web site at www. neurology.org). There are unique costs and qual-
ity of life values (utilities) associated with each health state. Analyses
were continued until all individuals in the hypothetical cohorts had
died from their aneurysm or other causes.
Preventive treatment option. Patients who underwent
preventive occlusion may have died during or immediately
after the intervention, survived with a mild or moderate to
severe disability, or survived with normal neurologic func-
tion. Surgical clipping was assumed to eliminate the risk of
SAH at least in the first year. However, a small possibility of
regrowth and rupture of the clipped aneurysm remained in
subsequent years. Endovascular coiling was assumed to pro-
vide partial protection against aneurysm rupture, since in-
complete occlusion was obtained in a substantial proportion
of aneurysms. Also, reopening of the aneurysm has been
shown to occur over time. All persons with a treated aneu-
rysm, either by clipping or coiling, still carried a risk of SAH
because of formation of de novo aneurysms over time.
No preventive treatment option. The no-treatment op-
tion did not involve the initial procedure-related risk, but obviously
there was a persistent risk of aneurysm rupture. All patients in
whom an SAH developed were supposed to undergo optimal treat-
ment. Patients with SAH may die before hospitalization or during
or immediately after treatment for SAH, may survive with a mild or
moderate to severe disability, or may completely recover after SAH.
All surviving patients still carried a risk of SAH because of formation
of de novo aneurysms over time.
Model estimates: Clinical assumptions. We retrieved the
transition probabilities for our model from the literature (table 1).
Risk of rupture in untreated aneurysms. The reported
rupture risks of an unruptured intracranial aneurysm vary from
nil to 2.3% per year.4,12-17 A recent meta-analysis reported an
overall rupture risk of 0.9% per year.17 Aneurysm rupture risks
vary depending on patient characteristics (age, gender) and aneu-
rysm characteristics (size, location) and whether there is a history
of SAH from a different aneurysm.17 To account for variable
aneurysm characteristics, we modeled eight different rupture risk
scenarios (range, 0.3–3.5% per year).
Risks of complications from preventive treatment. We
used both ISUIA data and results from reviews on mortality and
morbidity rates of preventive treatment in general.4,18,19 We used
a treatment-related mortality rate of clipping of 1.8% and a mor-
bidity rate of 5.6%.4,18 For coiling, we used a treatment-related
mortality rate of 0.6% and a morbidity rate of 7%.19 We as-
sumed that half of the patients with surgical morbidity and one-
third of patients with endovascular morbidity became
moderately to severely disabled.4,18,19
Risk of development of a regrowth, reopening, or de novo
aneurysm. After clipping, a regrowth rate of 0.3 to 0.5% per year
has been reported.20-23 We used a regrowth rate of 0.4% per year in
the first 10 years after clipping. The main concerns with endovascu-
lar treatment are the substantial proportion of aneurysms that are
incompletely occluded initially and the possibility of reopening of
the aneurysm over time. Reported aneurysmal recurrence rates were
14% in the first 12 months, 5% in the second year, and 2% in the
third year after initial coiling treatment.24,25 Half of the patients with
a recurrence were assumed to receive additional treatment.24,25 We
assumed that additional treatment eliminated the risk of subsequent
SAH. The risk of rupture for aneurysms that did not undergo re-
treatment was assumed to be equal to the risk of the initially coiled
aneurysm. The development of de novo aneurysms varied between
0.5 and 0.9% per year in low-risk populations.21,22,26 We used a de
novo formation rate of 0.5% per year.
Risk of rupture of regrowth, reopening, or de novo aneu-
rysms. The reported rupture risks for additional aneurysms do not
differ from rupture rates of incidentally found unruptured aneu-
rysms.17,27 Therefore, we used similar rupture rates for incidental
and recurrent aneurysms. Since we did not take into account nor
were interested in the possible effects of repeated diagnostic follow-
up, we used a constant average rupture risk (i.e., 0.9%/year) for de
novo aneurysms.17 We assumed that a regrowth or de novo aneu-
rysm could not rupture until 5 years after development.22
Risk of death and disability. Age- and sex-specific annual
mortality rates were taken from national life tables.28 The reported
case fatality rates after SAH vary from 21% to 44%.2,3 We assumed
a case fatality rate of 35%, that 9%who survived their bleed became
permanently severely disabled, and that 15% became mildly dis-
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abled.2,3 The proportion of patients with SAH who died before re-
ceiving medical attention was assumed to be 12%.1 Patients who
survived their bleed and were left disabled experience excess mortal-
ity compared with the general population.29We therefore assumed a
twofold increased risk of dying in moderately to severely disabled
patients. Patients with an unruptured aneurysm may also have a
reduced life expectancy due to the presence of vascular disease. We
accounted for this in the sensitivity analysis.
Utilities. Benefits were measured in QALYs. Utility weights for
the health states minor disability (0.72) and moderate to severe
disability (0.41) were derived from data published in the litera-
ture.30 Awareness of having an untreated aneurysm that may at
any time rupture with inherent catastrophic effects may nega-
tively influence quality of life. For this impact of the awareness of
having an untreated aneurysm, we estimated a utility of 0.92.31
Costs. We conducted our economic analysis from the health-
care payer perspective. A recent Dutch study details the direct
costs associated with preventive aneurysm occlusion.32 From
these data, we estimated that the costs of these treatments and
the control visits and examinations were €8,672 for clipping and
Table 1 Transition probabilities, utilities, and costs used in theMarkovmodel
Variables Estimate Range Distribution Data source* Reference
Surgical clipping
Procedure-related death 1.8% 1.2–2.5% Beta Meta-analysis 4, 18
Permanentmoderate to severe disability 2.8% 2.2–3.5% Beta Meta-analysis 4, 18
Permanent mild disability 2.8% 2.2–3.5% Beta Meta-analysis 4, 18
Regrowth rate after clipping/year 0.4% 0.3–0.5% Uniform Cohort study 20, 21, 23
Endovascular coiling
Procedure-related death 0.6% 0.2–1.0% Beta Meta-analysis 4, 19
Permanentmoderate to severe disability 2.2% 1.3–3.4% Beta Meta-analysis 4, 19
Permanent mild disability 4.8% 3.4–6.5% Beta Meta-analysis 4, 19
Reopening
First year after coiling 14% 11–17% Uniform Cohort study 24, 25
Second year after coiling 5% 3–7% Uniform Cohort study 24, 25
Third year after coiling 2% 1–3% Uniform Cohort study 24, 25
De novo aneurysms
De novo aneurysm formation/year 0.5% 0.3–0.8% Beta Cohort study 21, 22, 26
Risk of rupture de novo/year 0.9% 0.7–1.0% Beta Meta-analysis 17
SAH
Death before reaching the hospital 12% 11–14% Beta Meta-analysis 1
Case fatality (at 1 yr) 35% 25–45% Beta Meta-analysis 2, 3
Moderate to severe disability 9% 7–11% Beta Meta-analysis 2, 3




SMRmoderate to severe disability 2.0 1.0–3.0 Triangular Cohort study 29
Utilities
Permanentmoderate to severe disability 0.41 0.25–0.65 Triangular Review 30
Permanent mild disability 0.72 0.65–0.80 Triangular Review 30
Awareness of an untreated aneurysm 0.92 0.87–1.0 Triangular Case-control
study
31
Costs (in 2005 Euros)
Preventive clipping 8,672 — — Cohort study 32
Preventive coiling 10,440 — — Cohort study 32
Treatment after SAH 26,561 — — Cohort study 33
Death 2,579 — — Expert opinion 34
Moderate to severe disability 20,194 — — Cost study 34
Mild disability 1,038 — — Cost study 34
*When multiple publications were used, the study type with the strongest study design was mentioned.
SMR standardized mortality rate; SAH subarachnoid hemorrhage.
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€10,440 for coiling. Costs of SAH in the first year after diagnosis
were derived from a multicenter study in The Netherlands and
were estimated at €26,561.33 The annual costs of care for dis-
abled patients after preventive treatment or SAH were taken
from data on long-term care in stroke patients.34 The model does
not account for any costs of diagnostic follow-up in the no-
treatment arm. All cost estimates were updated to 2005 Euros
based on Dutch inflation indices (http://statline.cbs.nl).
Cost-effectiveness and sensitivity analysis. We modeled
eight different rupture risk scenarios (ranging from 0.3 to 3.5%)
for 50-year-old and 70-year-old men and women separately. Al-
though standard practice in cost-effectiveness analysis is to com-
pare each treatment with the next best option, we chose to
compare both preventive treatments with no treatment, as our
aim in this study was to decide which unruptured intracranial
aneurysms should be treated. Incremental cost-effectiveness ra-
tios (ICER) were defined as the difference in costs divided by the
difference in QALYs. Treatment was considered cost-effective at
an ICER of €20,000 per QALY gained. Both costs and effects
were discounted at 4%.
Extensive sensitivity analyses were performed by altering the
input values for individual variables, with plausible ranges of
values as given in table 1. To assess the combined uncertainty
embedded in all input variables simultaneously, we performed
probabilistic sensitivity analyses with Monte Carlo simulation.
For each simulation of the model, a value of each input variable
was selected randomly from its distribution.35 Additionally, we
conducted scenario analyses on 1) increase in surgical risk of
death or severe disability for 70-year-old patients, 2) excess mor-
tality for patients with unruptured aneurysms, and 3) the impact
of indirect costs according to the friction cost method.4,29,36 Pa-
tients were assumed to be absent from work for 4 weeks after
clipping and 1.5 weeks after coiling. Dutch workforce participa-
tion rates were obtained from Dutch Bureau of Statistics data
(http://statline.cbs.nl). All analyses were conducted in TreeAge
(TreeAge Pro Suite 2008, Williamstown, VA).
RESULTS Treatment of intracranial unruptured an-
eurysms reduced the risk of future SAH. For aneu-
rysms with a rupture risk of 1%/year in 50-year-old
men, the predicted probability of SAH during the
remaining lifetime was 22.8% without preventive
treatment. This risk was only 1.6% after clipping and
3.4% after coiling (table 2). For 70-year-old men, the
lifetime risk of SAH decreased from 10.2% in case
no treatment would be offered to 0.3% after clipping
and 1.3% after coiling. The predicted probability of
de novo aneurysm formation decreased with age
from 11% to 5% in men initially aged 50 vs 70 years.
A regrowth was predicted to occur in 3% of all
clipped patients and a reopening occurred in approx-
imately 20% of all coiled patients. The predicted life-
time risks of SAH and de novo aneurysm formation
were slightly higher in women, since women have
higher life expectancies than men.
Cost-effectiveness analyses. For 50-year-old men,
both preventive treatments resulted in a net QALY
gain ranging from 0.9 to 2.3 QALY for rupture rates
between 0.3% and 3.5%/year (table 3). The magni-
tude of benefit of treatment decreased with age, but
was still present for patients aged 70 years (net bene-
fit ranging from 0.4 to 0.9 QALY). In general, the
benefit of treatment was somewhat greater in wom-
en: net benefit ranged from 1.0 to 2.7 QALY in 50-
year-old women and ranged from 0.6 to 1.2 QALY
in 70-year-old women (table e-1). Both treatments
were cost-effective for all rupture rate scenarios be-
tween 0.3% and 3.5% per year in 50-year-old men
and women (table 3 and table e-1). For rupture rates
of 0.3%/year in 50-year-old men, ICERs were
€19,818/QALY for clipping and €18,588/QALY for
coiling. For higher rupture rates of 3.5%/year, the
ICERs decreased considerably to €940/QALY for
clipping and €2,194/QALY for coiling. For 70-year-
old men with a rupture rate up to 1%/year, no treat-
ment appeared the preferred option. Either
treatment would become cost-effective with rupture
rates surpassing 1%/year for men and 0.5%/year for
women.
Sensitivity analyses. These results were sensitive to 1)
the utility of awareness of an untreated aneurysm and
2) the treatment-related moderate to severe disabil-
ity. With increasing disutility, the cost-effectiveness
of treatment substantially improved (figure). Increas-
ing the surgical risk of death or moderate to severe
disability for 70-year-old patients resulted in consid-
erably higher ICERs (for example, at a twofold
higher risk of poor surgical outcome, the ICER in-
creased from €15,491/QALY to approximately
€66,000/QALY in 70-year-old men with a rupture
rate of 1.5%/year), making clipping cost-ineffective
Table 2 Simulated lifetime effects (mean of 2,000 iterations in cohorts of
50,000 patients) in each treatment strategy for formation and
rupture of aneurysms with a rupture rate of 1%/year
Men Women
Age, y 50 70 50 70
Formation of aneurysms
De novo aneurysm
No treatment 11.4 5.1 13.1 6.6
Surgical treatment 11.2 4.8 12.9 6.4
Endovascular treatment 11.4 4.9 13.2 6.5
Aneurysm regrowth
Surgical treatment 3.4 2.8 3.5 3.1
Aneurysm reopening
Endovascular treatment 19.8 19.4 19.8 19.6
Future SAH risk
No treatment 22.8 10.2 26.3 13.3
Surgical treatment 1.6 0.3 2.1 0.5
Endovascular treatment 3.4 1.3 4.1 1.7
Values are percentages.
SAH subarachnoid hemorrhage.
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for older patients. Assuming that patients with an
unruptured aneurysm have a twofold increased risk
of dying compared with the general population due
to the presence of vascular disease reduced the cost-
effectiveness of treatment slightly (for example, the
ICER for clipping increased from €19,818 to
€22,298 in 50-year-old men with a rupture rate of
0.3%/year). Taking indirect costs into consideration,
the ICERs increased somewhat (€24,629/QALY for
clipping and €20,170/QALY for coiling in 50-year-
old men with a rupture rate of 0.3%/year). The re-
maining probability estimates, including development
of de novo and recurrent aneurysms, had no relevant
impact on the incremental cost-effectiveness ratios
when varied over a wide range.
DISCUSSION This cost-effectiveness analysis
showed that preventive treatment of intracranial an-
eurysms is cost-effective in middle-aged patients for
all rupture rate scenarios between 0.3% and 3.5%
per year. Surgical and endovascular treatments have
both a substantial treatment benefit and are generally
equally cost-effective. For 70-year-old patients, treat-
ment of unruptured aneurysms is no longer cost-
effective in men with rupture rates 1%/year and
women with rupture rates 0.5%/year. Overall, the
analysis implies that patients’ life expectancy, risk of
rupture, and utility of awareness of an untreated an-
eurysm mainly define when treatment becomes cost-
effective. The effect of excess mortality risks, if
present in these persons at all, on the incremental
cost-effectiveness ratios was small. The risk of forma-
tion of recurrent and de novo aneurysms had no rel-
evant impact on the cost-effectiveness ratios.
In the current cost-effectiveness analysis, several
new aspects were introduced to overcome a number
of potential limitations in existing studies (table 4,
top). Previous cost-effectiveness analyses have dem-
onstrated that treatment of unruptured aneurysm in
50-year-old patients becomes cost-effective when the
rupture rate is about 1%/year.7,8 Another study re-
ported that treatment was cost-effective for aneu-
rysms that are 13 mm located in the anterior
circulation and 7- to 12-mm aneurysms located in
the posterior location, i.e., aneurysms with a yearly
rupture rate above 3%.11 However, those findings
were based on earlier estimates of complications,
risks, or results of the prospective ISUIA data only.4
Figure Sensitivity analyses on the effect of decreasing utility for awareness
of having an untreated aneurysm (horizontal axis) and annual
rupture rate on quality-adjusted life-year (QALY) and incremental
costs per QALY
For a 50-year-old man, aneurysm treatment was more effective than no treatment unless
the rupture rate was 0.5%/year and the utility for being aware of an untreated aneurysm
was greater than 0.98. The incremental cost-effectiveness ratios for both treatmentswere
below the €20,000 per QALY threshold for rupture rates of 0.5%/year and utilities lower
than 0.94 for awareness of having an untreated aneurysm.
Table 4 What is new in this cost-
effectiveness analysis and
remaining areas of uncertainty
What is new?
● Use of complications and risks of clipping and coiling not
only based on ISUIA data
● Risk formation and rupture of recurrent and de novo
aneurysms taken into account
● Use of a utility for awareness of an untreated aneurysm
based on a study that assessed the perceived burden of
finding small aneurysms that are left untreated
● Costs of repeated endovascular treatments taken into
account
● Use of recent, accurate cost estimates of preventive
clipping and coiling
● Identification of areas of uncertainty
Remaining areas of uncertainty
● Reliable estimation of utility of awareness of untreated
aneurysm for presenting person
● Risk of aneurysm rupture according to size and location:
multivariable estimates needed
● Treatment-related complication risks according to age
and aneurysm size and location
● Natural excess mortality in persons with unruptured
aneurysms
● Rebleeding risk after incomplete endovascular treatment
ISUIA  International Study of Unruptured Intracranial
Aneurysms.
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Despite the merits of being the largest prospective
study on risk of rupture of unruptured intracranial
aneurysms, the ISUIA study has several important
weaknesses and therefore should be interpreted with
caution.5,6 Furthermore, in previous cost-effectiveness
analyses of unruptured aneurysm treatment, there
was a tendency for endovascular treatment to be
more cost-effective than surgical treatment.9,11 How-
ever, these studies did not consider the costs of addi-
tional treatments and therefore underestimated the
costs of endovascular treatment. In addition, more
accurate cost estimates for surgical and endovascular
treatments (in particular the higher costs of coils)
have become available.32 Furthermore, the risk of for-
mation and rupture of recurrent and de novo aneu-
rysms were not included in these models.
Our study has certain limitations. Since it is un-
clear how incomplete endovascular occlusion affects
rupture risk, we assumed a rupture risk for an incom-
pletely occluded aneurysm or reopened aneurysm
that was equal to rupture risk of the initially coiled
aneurysm. Health benefits of endovascular treatment
may, therefore, have been underestimated. Second,
we assumed that all unruptured intracranial aneu-
rysms had the same treatment-related morbidity and
mortality rates, while the ISUIA reported that treat-
ment outcomes varied depending on aneurysm size
and location.4 Furthermore, surgical outcomes seem
to be dependent on patient age.4 Notably, as the risk
of surgery increases with age, the preferable method
for treatment of unruptured aneurysms for older pa-
tients would be endovascular treatment. However,
this also depends on the experience and results
of treating clinics. Third, we assumed that preventive
treatment costs were constant across different rup-
ture rate scenarios (i.e., for smaller vs larger aneu-
rysms), because size-specific data for treatment costs
were lacking. Therefore, costs and cost-effectiveness
ratios may in fact be somewhat higher for treatment
of larger aneurysms, but somewhat lower for smaller
aneurysms. Fourth, health care costs in the United
States and other countries may be different from
Dutch cost estimates. A global increase in costs, e.g.,
in accordance with differences between US and
Dutch cost estimates, would result in higher cost-
effectiveness ratios, which would reduce the yield for
preventive treatment in small aneurysms. Finally, we
conducted our economic analysis from the healthcare
payer perspective (including only direct medical
costs). With a societal perspective (additionally in-
cluding indirect costs), the incremental cost-
effectiveness estimates changed marginally.
We identified several remaining areas of uncer-
tainty (table 4, bottom). Our results were highly sen-
sitive to the utility of awareness of an untreated
aneurysm. Only a slight decrease in quality of life
from the awareness of an untreated aneurysm led to a
substantial increase in the incremental cost-
effectiveness ratio of treatment. Regrettably, little is
known about the utility in patients who are aware of
an increased health risk, but refrained from treat-
ment, and about modifying factors. Aneurysm rup-
ture risks are known to increase with larger size,
posterior circulation aneurysms, older age, and fe-
male gender.17 Also, it is likely that some of these
characteristics are not independent. However, since
data currently available in the literature did not allow
performing multivariable analysis, uncertainty in the
estimation of individual aneurysmal rupture risk will
remain. Questions about excess mortality in persons
with unruptured aneurysms and rupture risk after in-
complete coiling remain unanswered, but their influ-
ence on cost-effectiveness will be limited.
Our results may help physicians and patients in
deciding whether preventive aneurysm occlusion
would be justified based on the estimated rupture
risk and perceived burden of an untreated aneurysm.
For more refined cost-effectiveness analyses and indi-
vidualized risk estimates, more data on risk of rup-
ture according to size and location of aneurysms and
on the utility of the awareness of an untreated aneu-
rysm are needed.
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